AbbVie Inc. (ABBV) reported fourth-quarter and full-year 2025 results, highlighting neuroscience segment sales of $10.8 billion, which accounted for approximately 18% of total revenues. This segment saw a nearly 20% year-over-year increase, driven by strong sales of Botox Therapeutic, Vraylar, Qulipta, and Ubrelvy. New Parkinson’s disease (PD) therapy Vyalev generated $482 million in sales, with expectations for the neuroscience franchise to reach $12.5 billion in 2026, marking a 16% growth projection.
AbbVie is also seeking FDA approval for tavapadon, a once-daily oral therapy for PD, with potential launch later this year. The company aims for Vyalev to exceed $1 billion in global sales within its first two years, bolstering its position in the neuroscience market.
